Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
20 June 2024 | Story Jacky Tshokwe | Photo Suplied
Dr Mutshidzi Mulondo
Dr Mutshidzi Mulondo’s achievements not only highlight her personal dedication and growth, but further reflect the University of the Free State’s unwavering commitment to Vision 130’s goals of academic excellence, leadership, and global engagement.

The University of the Free State (UFS) takes immense pride in the remarkable achievements of Dr Mutshidzi Mulondo, an academic in the Faculty of Health Sciences. Her international recognition and appointments not only exemplify her dedication to academic excellence and leadership but also reflect the UFS’ commitment to nurturing researchers who are globally competitive and internationally well connected, aligning perfectly with Vision 130.

Dr Mulondo was recently appointed to the International Council of Advisers as council member in the Golden Key International Honour Society. Golden Key, the world's largest collegiate honour society, selects the top 15% of high academic achievers in a college or university. In this role, Dr Mulondo will represent South Africa and oversee more than 20 (all) academic institutional chapters in South Africa. Her passion for academic excellence and leadership development is evident, as she strives to nurture these qualities among students, further ensuring that they remain socially engaged, in the spirit of ubuntu. “Education is one of the keys to eradicating poverty. While academic excellence can set graduates apart, we must continue to encourage and celebrate this excellence among our students and youth – not just this Youth Month but every other month. I am honoured to amplify an organisation such as Golden Key that shares these values,” says Dr Mulondo.

This commitment to academic and leadership excellence is a cornerstone of the UFS’ mission. The strategic objectives aim to enhance research capabilities and promote leadership, creating an environment where students and staff can thrive and make significant contributions to society.

Dr Mulondo’s recent accomplishments extend beyond her council and advisory role. She was awarded an impact-oriented grant for emerging researchers under the University Partnership Initiative, allowing her to strengthen her collaborative research partnership with the Appalachian State University (AppState). As a Public Health visiting scholar at AppState’s Beaver College of Health Sciences, she worked with academic host Dr Tandrea Carter, and collaborators Prof Martie Thompson and Prof Adam Hege. Her visit in the last term of 2023 culminated in a presentation of preliminary findings at the Global Symposium, USA. This public health partnership highlights the continuing collaboration initiated during her time as a Mandela Washington Fellow in 2022. This partnership underscores the UFS’ commitment to global engagement and fostering partnerships that enhance educational and research agenda.

Her global impact is further recognised, as she was selected globally as one of 10 Reimagining Healthcare Scholars by Novartis in 2023. Representing South Africa, she joined young global scholars at the One Young World Summit in the United Kingdom. The summit gathered delegates from 192 countries to address pressing global issues such as mental health, climate change, and food security. “As emerging scholars, it is essential to stay engaged locally and globally if we must remain innovative,” says Dr Mulondo, who is now a One Young World Ambassador. Her participation underscores the UFS’ dedication to nurturing staff members who address global challenges and aligns with the vision of fostering academic excellence and social responsibility.

“It is no surprise that Dr Mulondo has been appointed and selected for these various global roles and accolades, as she has continued to display the UFS Vision 130’s values of academic and leadership excellence on a global stage, further evidenced by her selection to the university’s Emerging Scholar Accelerator Programme (ESAP),” says Prof Joyce Tsoka-Gwegweni, Vice-Dean: Research and Head of Public Health. This advanced residential programme identifies the most promising academics who have obtained a doctoral degree within the last five years. Dr Mulondo’s dedication to academic excellence and leadership is commendable.

Reflecting on her journey as an emerging researcher in the newly established Division of Public Health, Dr Mulondo expressed gratitude for the supportive environment at the UFS. “I am grateful for the enabling environment that the UFS provides to emerging researchers and academics through programmes such as ESAP. I look forward to continued growth and I continue to be fuelled by my favourite passages of Scripture. ‘Let no one despise your youth, but be an example to the believers in word, in conduct, in love, in spirit, in faith and in purity.’ For the people who know their God will truly be strong and will carry out great exploits.” (1 Timothy 4:12; Daniel 11:32).

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept